company background image
0RFI logo

BRAIN Biotech LSE:0RFI Stock Report

Last Price

€3.48

Market Cap

€75.2m

7D

2.1%

1Y

n/a

Updated

27 Dec, 2024

Data

Company Financials +

0RFI Stock Overview

Engages in the research and development of Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. More details

0RFI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

BRAIN Biotech AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for BRAIN Biotech
Historical stock prices
Current Share Price€3.48
52 Week High€4.47
52 Week Low€1.47
Beta1.2
1 Month Change5.14%
3 Month Change57.47%
1 Year Changen/a
3 Year Change-61.75%
5 Year Change-69.83%
Change since IPO-62.98%

Recent News & Updates

Recent updates

Shareholder Returns

0RFIGB ChemicalsGB Market
7D2.1%2.0%0.5%
1Yn/a-24.9%2.7%

Return vs Industry: Insufficient data to determine how 0RFI performed against the UK Chemicals industry.

Return vs Market: Insufficient data to determine how 0RFI performed against the UK Market.

Price Volatility

Is 0RFI's price volatile compared to industry and market?
0RFI volatility
0RFI Average Weekly Movement17.3%
Chemicals Industry Average Movement6.0%
Market Average Movement4.7%
10% most volatile stocks in GB Market10.5%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0RFI's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0RFI's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993319Aryan Moelkerwww.brain-biotech.com

BRAIN Biotech AG engages in the research and development of Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. It operates in three segments: BioProducts, BioScience, and BioIncubator. The company offers enzymes and biocatalysts to produce food and beverages, wound care preparations or lubricants, and production of starch and bioethanol; and microorganisms as the functional biomass for optimized industrial production processes, recycling of the greenhouse gas CO2 as an industrial raw material, and urban and green mining for extraction of precious and rare earth metals.

BRAIN Biotech AG Fundamentals Summary

How do BRAIN Biotech's earnings and revenue compare to its market cap?
0RFI fundamental statistics
Market cap€75.16m
Earnings (TTM)-€8.77m
Revenue (TTM)€56.26m

1.3x

P/S Ratio

-8.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RFI income statement (TTM)
Revenue€56.26m
Cost of Revenue€24.98m
Gross Profit€31.29m
Other Expenses€40.06m
Earnings-€8.77m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Jan 15, 2025

Earnings per share (EPS)-0.40
Gross Margin55.61%
Net Profit Margin-15.59%
Debt/Equity Ratio0%

How did 0RFI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 19:49
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BRAIN Biotech AG is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Volker BosseBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research
Laura Lopez PinedaBaader Helvea Equity Research